Business
Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido® Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets ...
Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido®
About this update from Scilex Holding Company
[{"type":"text","content":"Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido® Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region \n ACEA Therapeutics (“ACEA”) will serve as exclusive territories distributor in Greater China, including mainland China, Taiwan, Hong Kong and Macau, with potential minimum purchase commitment for ZTlido once approved locally in the region.ACEA to immediately start the process to explore potential commercialization of ZTlido®, with the opportunity to distribute with partners across Greater China and further expand the relationship to include other products in Scilex’s non-opioid pain portfolio. PALO ALTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that that it has entered into a Memorandum of Understanding (MOU) for collaboration agreement with ACEA, a China-based company focused on the development of innovative treatments for high unmet needs. Under the terms of the MOU, ACEA may receive exclusive rights to develop and commercialize of ZTlido® in mainland China, Taiwan, Hong Kong, Macau, including the current formulation and a right of first negotiation for a future next generation formulation of a 3X version of ZTlido, SP-103. The MOU provides Scilex with the opportunity to expand collaboration with ACEA across other products in Scilex’s non-opioid pain management portfolio in the Greater China region. ZTlido® is a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia or PHN. ZTlido® was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. According to the most recent analysis by Precedence Research March 2022 Pain Management Therapeutics Market Size, the pain management market size is estimated to reach US$101.27 billion by 2029 and growing at a CAGR of 4.3% from 2022 to 2030.1 In mainland China, the ...